BCRX: It would be difficult to compete against RDEA594, the drug AZN acquired, in exactly same patient population: http://investorcenter.ardeabio.com/phoenix.zhtml?c=122089&p=irol-newsArticle&ID=1513841&highlight= By the way, RDEA594 press release is one of the best PR I have seen in the industry by giving precise disease background, trial design, results from different statistical analysis methods, and safety profiles from all arms.
Market Data 
Markets 
AI
